Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.13 USD -4.47%
Market Cap: 1.3B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Gross Margin
Maravai LifeSciences Holdings Inc

46.4%
Current
68%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.4%
=
Gross Profit
128.4m
/
Revenue
276.9m

Gross Margin Across Competitors

Country US
Market Cap 1.3B USD
Gross Margin
46%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 200.4B USD
Gross Margin
41%
Country US
Market Cap 165.4B USD
Gross Margin
60%
Country KR
Market Cap 66.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 35.9B USD
Gross Margin
35%
Country US
Market Cap 26.8B USD
Gross Margin
59%
Country US
Market Cap 24.1B USD
Gross Margin
35%
Country CN
Market Cap 164.4B CNY
Gross Margin
40%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Life Sciences Tools & Services

Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.

MRVI Intrinsic Value
2.89 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.4%
=
Gross Profit
128.4m
/
Revenue
276.9m
What is the Gross Margin of Maravai LifeSciences Holdings Inc?

Based on Maravai LifeSciences Holdings Inc's most recent financial statements, the company has Gross Margin of 46.4%.